Literature DB >> 20568902

Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.

P Stehlik1, H Paulikova, L Hunakova.   

Abstract

Isothiocyanates (ITCs), popular chemopreventive agents present in cruciferous vegetables, prove growth-inhibiting and apoptosis-inducing activities in cancer cell lines in vitro. Our study presents a new synthetic ITC derivate indol-3-ethyl isothiocyanate (homoITC) as an effective modulator of cellular proliferation and inducer of apoptosis with potential utility as an anticancer drug or a sensitizer to routinely used chemotherapeutic agent cisplatin (cis-Pt).<br />We analyzed the growth inhibitory effects of homoITC in the human ovarian carcinoma cell line A2780 and its cisplatin-resistant variant A2780/CP using MTT-test and its apoptosis-inducing properties by flow cytometry and caspase 3 activation. Combination index (CI) values from Calcusyn software were used to characterize the interactions of homoITC and cis-Pt as synergistic (CI1). Significant synergistic effect in growth inhibition of homoITC (5 - 15 microM) and cis-Pt (2.5 - 10 microM) on A2780 parental cell line (CI from 0.42 to 0.85) was also observed on A2780/CP resistant subline (CI from 0.18 to 0.73) for 10-50 microM cis-Pt concentrations and the same concentrations of homoITC. Synergy in growth inhibition correlated with the potential of homoITC to stimulate apoptosis induced by cis-Pt.We conclude that homoITC may be worth of further studies assessing its value in the ovarian cancer treatment and elucidating mechanisms of its action.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20568902     DOI: 10.4149/neo_2010_05_473

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo.

Authors:  Xiang Ling; David Westover; Felicia Cao; Shousong Cao; Xiang He; Hak-Ryul Kim; Yuesheng Zhang; Daniel Cf Chan; Fengzhi Li
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.

Authors:  Miroslava Matuskova; Zuzana Kozovska; Lenka Toro; Erika Durinikova; Silvia Tyciakova; Zuzana Cierna; Roman Bohovic; Lucia Kucerova
Journal:  J Exp Clin Cancer Res       Date:  2015-04-09

3.  Genotoxic Effects of Tributyltin and Triphenyltin Isothiocyanates, Cognate RXR Ligands: Comparison in Human Breast Carcinoma MCF 7 and MDA-MB-231 Cells.

Authors:  Luba Hunakova; Eva Horvathova; Karolina Majerova; Pavel Bobal; Jan Otevrel; Julius Brtko
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

4.  Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.

Authors:  Silvia Schmidtova; Katarina Kalavska; Katarina Gercakova; Zuzana Cierna; Svetlana Miklikova; Bozena Smolkova; Verona Buocikova; Viera Miskovska; Erika Durinikova; Monika Burikova; Michal Chovanec; Miroslava Matuskova; Michal Mego; Lucia Kucerova
Journal:  Cancers (Basel)       Date:  2019-08-22       Impact factor: 6.639

5.  Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.

Authors:  Silvia Schmidtova; Katarina Kalavska; Veronika Liskova; Jana Plava; Svetlana Miklikova; Lucia Kucerova; Miroslava Matuskova; Lucia Rojikova; Zuzana Cierna; Adriana Rogozea; Heiko Konig; Costantine Albany; Michal Mego; Michal Chovanec
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

6.  Pre-diagnosis Cruciferous Vegetables and Isothiocyanates Intake and Ovarian Cancer Survival: A Prospective Cohort Study.

Authors:  Yi-Fan Wei; Ying-Ying Hao; Song Gao; Xiu-Qin Li; Fang-Hua Liu; Zhao-Yan Wen; Han-Yuan Wang; Shuang Zhang; Shi Yan; Meng Luan; Yu-Hong Zhao; Ting-Ting Gong; Qi-Jun Wu
Journal:  Front Nutr       Date:  2021-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.